ArticleEMBO reports2009
RYBP stabilizes p53 by modulating MDM2.
Article in EMBO reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 87 citations in OpenAlex.
- Nucleomodulins from gut bacteria: diverse mechanisms of translocation and interaction with host nuclear processes.Applied and environmental microbiology · 2025Review
- De novo variants in RYBP are associated with a severe neurodevelopmental disorder and congenital anomalies.Genetics in medicine : official journal of the American College of Medical Genetics · 2025Article
- Unveiling the Binding between the Armadillo-Repeat Domain of Plakophilin 1 and the Intrinsically Disordered Transcriptional Repressor RYBP.Biomolecules · 2024Article
- RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity.International journal of oncology · 2023Article
- Sex-biased genome-editing effects of CRISPR-Cas9 across cancer cells dependent on p53 status.iScience · 2023Article
- Upregulation of circRNA hsa_circ_0008726 in Pre-eclampsia Inhibits Trophoblast Migration, Invasion, and EMT by Regulating miR-345-3p/RYBP Axis.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in lung adenocarcinoma cells.Journal of experimental & clinical cancer research : CR · 2022Article
- RYBP modulates embryonic neurogenesis involving the Notch signaling pathway in a PRC1-independent pattern.Stem cell reports · 2021Article
- Characterization of Biological Pathways Regulating Acute Cold Resistance of Zebrafish.International journal of molecular sciences · 2021Article
- Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.Cancer letters · 2021Review
- Bacterial nucleomodulins and cancer: An unresolved enigma.Translational oncology · 2021Review
- Mdm2: Open questions.Cancer science · 2020Review
- From Gene to Protein-How Bacterial Virulence Factors Manipulate Host Gene Expression During Infection.International journal of molecular sciences · 2020Review
- Review
- Low Expression of the Polycomb Protein RING1 Predicts Poor Prognosis in Human Breast Cancer.Frontiers in oncology · 2020Article
- Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.BMC cancer · 2019Article
- The versatile nature of miR-9/9Oncotarget · 2018Review
- Multiple roles of Ring 1 and YY1 binding protein in physiology and disease.Journal of cellular and molecular medicine · 2018Review
- OrfX, a Nucleomodulin Required formBio · 2017Article
- Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The mouse double minute 2 (MDM2)-p53 interaction regulates the activity of p53 and is a potential target for human cancer therapy. Here, we report that RYBP (RING1- and YY1-binding protein), a member of the polycomb group (PcG), interacts with MDM2 and decreases MDM2-mediated p53 ubiquitination, leading to stabilization of p53 and an increase in p53 activity. RYBP induces cell-cycle arrest and is involved in the p53 response to DNA damage. Expression of RYBP is decreased in human cancer tissues compared with adjacent normal tissues. These results show that RYBP is a new regulator of the MDM2-p53 loop and that it has tumour suppressor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.